213 related articles for article (PubMed ID: 35068446)
21. Identification of Gene-Tyrosine Kinase 2 (TYK2) in Head and Neck Squamous Cell Carcinoma Patients-An Integrated Bioinformatics Approach.
Gong X; Ren F
Dis Markers; 2022; 2022():5239033. PubMed ID: 35711568
[TBL] [Abstract][Full Text] [Related]
22. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
23. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
25. Prognostic biomarker GSTK1 in head and neck squamous cell carcinoma and its correlation with immune infiltration and DNA methylation.
Feng Y; Zhou YH; Zhao J; Su XL; Chen NX; Zhao YQ; Ye Q; Hu J; Ou-Yang ZY; Zhong MM; Yang YF; Han PJ; Guo Y; Feng YZ
Front Genet; 2023; 14():1041042. PubMed ID: 36936420
[No Abstract] [Full Text] [Related]
26. Natural killer cell-based signature: Prognostic analysis in head and neck squamous cell carcinoma.
Guo Z; Zhao Y; Xu M; Zhao L; Wang X
J Gene Med; 2024 Feb; 26(2):e3671. PubMed ID: 38384136
[TBL] [Abstract][Full Text] [Related]
27. Expression and prognostic analysis of BGN in head and neck squamous cell carcinoma.
Zhao L; Liang J; Zhong W; Han C; Liu D; Chen X
Gene; 2022 Jun; 827():146461. PubMed ID: 35358652
[TBL] [Abstract][Full Text] [Related]
28. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
Shi C; Liu S; Tian X; Wang X; Gao P
BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
[TBL] [Abstract][Full Text] [Related]
29. Interferon Regulatory Factor Family Genes: At the Crossroads between Immunity and Head and Neck Squamous Carcinoma.
Liu S; Wang Z
Dis Markers; 2022; 2022():2561673. PubMed ID: 35664436
[TBL] [Abstract][Full Text] [Related]
30. CCND1-associated ceRNA network reveal the critical pathway of TPRG1-AS1-hsa-miR-363-3p-MYO1B as a prognostic marker for head and neck squamous cell carcinoma.
Li Z; Qiu X; He Q; Fu X; Ji F; Tian X
Sci Rep; 2023 Jul; 13(1):11831. PubMed ID: 37481637
[TBL] [Abstract][Full Text] [Related]
31. Signal peptidase complex catalytic subunit SEC11A upregulation is a biomarker of poor prognosis in patients with head and neck squamous cell carcinoma.
Hu C; Fan J; He G; Dong C; Zhou S; Zheng Y
PLoS One; 2022; 17(6):e0269166. PubMed ID: 35653344
[TBL] [Abstract][Full Text] [Related]
32. Serum Aminoacyl-tRNA Synthetase-Interacting Multifunctional Protein-1 Can Predict Severe Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Pilot Monocentric Study.
Ahn SS; Kim JO; Yoon T; Song JJ; Park YB; Lee SW; Park SG
Biomed Res Int; 2019; 2019():7508240. PubMed ID: 31236412
[TBL] [Abstract][Full Text] [Related]
33. IGF2BP2 serves as a core m6A regulator in head and neck squamous cell carcinoma.
Hu Y; Chen J; Liu M; Feng Q; Peng H
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281789
[TBL] [Abstract][Full Text] [Related]
34. TRIB3, as a robust prognostic biomarker for HNSC, is associated with poor immune infiltration and cancer cell immune evasion.
Wu H; Fu Z; Li H; Fang F; He B; Ye Y; Wu H; Xu D; Zheng H; Zhang Q
Front Immunol; 2023; 14():1290839. PubMed ID: 38235126
[TBL] [Abstract][Full Text] [Related]
35. Identification of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma (HNSC) for the Exploration of Immunotherapy and Prognosis.
Huang C; Liu J
Genet Res (Camb); 2022; 2022():6880760. PubMed ID: 36636556
[TBL] [Abstract][Full Text] [Related]
36. AIMP1 negatively regulates adipogenesis by inhibiting PPARĪ³.
Kim JH; Lee JH; Park MC; Yoon I; Kim K; Lee M; Choi HS; Han JM; Kim S
J Cell Sci; 2014 Oct; 127(Pt 20):4483-93. PubMed ID: 25146391
[TBL] [Abstract][Full Text] [Related]
37.
Dai Y; Chen W; Huang J; Cui T
Biomed Res Int; 2021; 2021():8874578. PubMed ID: 34285919
[TBL] [Abstract][Full Text] [Related]
38. Non-coding RNA-mediated high expression of
Chen K; Gong S; Fang X; Li Q; Ye M; Li J; Huang S; Zhao Y; Liu N; Li Y; Ma J
Front Immunol; 2022; 13():920136. PubMed ID: 36159813
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of XRCC1 is Associated with Poor Survival in Patients with Head and Neck Squamous Carcinoma and Has Potential to Be Used as Targeted Therapy by Synthetic Lethality.
Ahirwar SS; Lasunte S; Gupta M; Chowdhary R; Kotnis A
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3525-3535. PubMed ID: 37898859
[TBL] [Abstract][Full Text] [Related]
40. CYP4F12 is a potential biomarker and inhibits cell migration of head and neck squamous cell carcinoma via EMT pathway.
Jia W; Chen S; Wei R; Yang X; Zhang M; Qian Y; Liu H; Lei D
Sci Rep; 2023 Jul; 13(1):10956. PubMed ID: 37414830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
